Inhaled Interferon Beta Increased Likelihood Of Recovery Among Hospitalized COVID-19 Patients, Preliminary Findings Show
Financial Times: Immunosuppressant drug shows promise for Covid-19 patients
“An initial trial showing that an immunosuppressant drug can significantly increase the likelihood of recovery among patients hospitalized by Covid-19 sent the share price of biotech company Synairgen soaring on Monday. In a study involving 101 patients from nine U.K. hospitals, those who were given interferon beta — which is commonly used to treat multiple sclerosis and thyroid dysfunction — were more than twice as likely to recover and were 79 percent less likely to develop a more severe version of the disease. Their breathlessness was also ‘markedly reduced,’ the company said…” (Gross/Mancini, 7/20).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.